Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $230.56 -2.38%
EPS Growth %: +174.9%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +174.9%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $6.34, $1.72 better than the analyst estimate of $4.62. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $981.08 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.25-4.5 billion, versus the consensus of $4.453 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
